Idera Pharmaceuticals Provides Update on Its Patent Portfolio
CAMBRIDGE, Mass., Aug 09, 2011 (BUSINESS WIRE) --
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today provided an update on its intellectual property portfolio. The Company's intellectual property portfolio now contains over 575 issued patents and pending patent applications covering compositions of matter and methods of use for Idera's technologies that include TLR-targeted immune modulatory oligonucleotides (IMO), gene silencing oligonucleotide (GSO) technology, and antisense technology. The Company also announced that it recently received the Patent Board's top impact score and that it was recognized for the 12th consecutive time over the past four years by the Patent Board(TM) as one of the top 35 companies in the biotechnology field based on its technology and intellectual property strength.
"The compounds claimed in our issued patents were created in-house using our nucleic acid chemistry expertise, and we are pleased that patent offices around the world continue to recognize the novelty, utility, and the diverse application of our technologies," commented Steven Ritter, Ph.D., J.D., Vice President of Intellectual Property and Contracts. "We believe achieving the top impact score and continuous top 35 ranking by the Patent Board is an independent affirmation of the strength of our science and intellectual property."
The Company's most recently issued U.S. patents include:
- US 7,812,000, entitled "Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends"
- US 7,833,538, US 7,824,696, and US 7,932,367, entitled "Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes"
- US 7,851,453 and US 7,863,250, entitled "Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides"
- US 7,851,454, entitled "Short immunomodulatory oligonucleotides"
- US 7,875,594, entitled "Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents"
- US 7,884,197 and US 7,960,362, entitled "Synthetic agonists of TLR9"
In addition to the issued U.S. patents, a patent corresponding to US 6,426,334 was granted in Canada, France, Germany, and Great Britain; a patent corresponding to US 6,476,000 was granted in Mexico; a patent corresponding to US 20050026861 was granted in Australia and Mexico; and a patent corresponding to US 7,427,405 was issued in Australia.
About Idera Pharmaceuticals' Intellectual
Property Portfolio
Idera's intellectual property
portfolio contains over 575 issued patents and pending patent
applications in countries around the world.
Immune Modulatory Oligonucleotides (IMO(R))
Idera's
IMO intellectual property portfolio contains over 315 patents and patent
applications in countries around the world owned by Idera and covering
its IMO technologies and includes claims covering novel agonists of TLRs
3, 7, 8, and 9 and antagonists of TLRs 7 and 9. These patents and patent
applications also include claims covering IMO-2055, IMO-2125, IMO-2134,
IMO-3100, and IMO-4200.
Gene Silencing Oligonucleotide (GSO) Technology
Idera's
GSO intellectual property portfolio contains five patent applications in
countries around the world owned by Idera and covering its GSO
technology. GSOs are single-stranded RNA or DNA constructs, with two
exposed 3'-ends, that are complementary to targeted mRNA or miRNA
sequences of therapeutic interest.
Antisense Technology
Idera's antisense
intellectual property portfolio contains over 255 patents and patent
applications in countries around the world owned or licensed by Idera
and covering novel antisense compositions and methods of their use.
These patents and patent applications include claims covering
second-generation antisense chemistry, oral delivery of
second-generation antisense compounds, and antisense compounds for
certain therapeutic targets.
About the Patent Board(TM)
The
Patent Board(TM) is an independent group that tracks and analyzes
intellectual property and technology assets across 17 industries
globally and publishes its results in the Wall Street Journal.
About Idera Pharmaceuticals, Inc.
Idera
Pharmaceuticals develops drug candidates to treat infectious diseases,
autoimmune and inflammatory diseases, cancer, and respiratory diseases,
and for use as vaccine adjuvants. Our proprietary drug candidates are
designed to modulate specific Toll-like Receptors, which are a family of
immune system receptors that direct immune system responses. Our
pioneering DNA and RNA chemistry expertise enables us to create drug
candidates for internal development and generates opportunities for
multiple collaborative alliances. For more information, visit www.iderapharma.com.
Idera Forward Looking Statements
This
press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause Idera's actual results to differ materially from those
indicated by such forward-looking statements, including the impact of
our strategic review on our plans for the development of our drug
candidates and technologies; whether results obtained in preclinical
studies and early clinical trials will be indicative of results obtained
in future clinical trials; whether products based on Idera's technology
will advance into or through the clinical trial process on a timely
basis or at all and receive approval from the United States Food and
Drug Administration or equivalent foreign regulatory agencies; whether,
if the Company's products receive approval, they will be successfully
distributed and marketed; whether the Company's collaborations with
Merck KGaA and Merck & Co, Inc., will be successful; whether the patents
and patent applications owned or licensed by the Company, such as the
patents and patent applications referred to on this release, will
protect the Company's technology and prevent others from infringing it;
whether Idera's cash resources will be sufficient to fund the Company's
operations; and such other important factors as are set forth under the
caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2011 which important factors are incorporated
herein by reference. Idera disclaims any intention or obligation to
update any forward-looking statements.
SOURCE: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com